オーストラリアにおける大うつ病性障害治療薬の市場予測及び分析(~2023)

調査会社GlobalData社が発行したリサーチレポート(データ管理コード:GDHC245CFR)
◆英語タイトル:PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023
◆発行会社/調査会社:GlobalData
◆商品コード:GDHC245CFR
◆発行日:2014年5月30日
◆調査対象地域:オーストラリア
◆ページ数:154
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD4,995 ⇒換算¥564,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD9,990 ⇒換算¥1,128,870見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD14,985 ⇒換算¥1,693,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[オーストラリアにおける大うつ病性障害治療薬の市場予測及び分析(~2023)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

PharmaPoint: Major Depressive Disorder – Australia Drug Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Despite patent expiries for key products, Eli Lilly’s Cymbalta in 2013, Otsuka Pharmaceutical/BMS’s Abilify in 2016, and AstraZeneca’s Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.

Scope

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Australia from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Major depressive disorder market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Australia.

*** レポート目次(コンテンツ)***

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Classification 17
3.3 Symptoms and Subtypes of Major Depressive Disorder 19
3.4 Prognosis 20
3.5 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.1.3 Clinical Practice 23
4.2 Australia 26
5 Competitive Assessment 29
5.1 Overview 29
5.2 Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors 31
5.2.1 Lexapro (Escitalopram) 31
5.2.2 Other Selective Serotonin Reuptake Inhibitors 35
5.3 Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors 38
5.3.1 Effexor (Venlafaxine) 38
5.3.2 Cymbalta (Duloxetine) 42
5.3.3 Pristiq (Desvenlafaxine) 46
5.4 Product Profiles: Major Brands, Other Antidepressants 50
5.4.1 Norepinephrine-Dopamine Reuptake Inhibitors 50
5.4.2 Noradrenaline and Specific Serotonergic Antidepressants 54
5.4.3 Monoamine Oxidase Inhibitors 58
5.4.4 Tricyclic Antidepressants 60
5.4.5 Brintellix (Vortioxetine) 62
5.5 Product Profiles: Major Brands, Antipsychotics 68
5.5.1 Abilify (Aripiprazole) 68
5.5.2 Seroquel XR (Quetiapine) 72
5.6 Other Therapeutic Classes 76
6 Unmet Needs and Opportunities 77
6.1 Overview 77
6.2 More Effective Pharmacotherapies 78
6.2.1 Unmet Needs 78
6.2.2 Gap Analysis 79
6.2.3 Opportunities 80
6.3 More Favorable Side Effect Profiles 80
6.3.1 Unmet Needs 80
6.3.2 Gap Analysis 81
6.3.3 Opportunities 81
6.4 Rapid Onset of Antidepressant Effects 82
6.4.1 Unmet Needs 82
6.4.2 Gap Analysis 82
6.4.3 Opportunities 82
6.5 Personalized Treatment Approach 83
6.5.1 Unmet Needs 83
6.5.2 Gap Analysis 84
6.5.3 Opportunities 84
7 Pipeline Assessment 85
7.1 Overview 85
7.2 Promising Drugs in Clinical Development 85
7.2.1 Brexpiprazole (OPC-34712) 88
7.2.2 Cariprazine (RGH-188) 94
7.2.3 ALKS-5461 99
7.2.4 Amitifadine (EB-1010) 104
7.2.5 GLYX-13 109
7.2.6 Tedatioxetine (Lu AA24530) 113
7.2.7 ETS6103 117
7.3 Other Drugs in Development 122
8 Market Outlook 124
8.1 Australia 124
8.1.1 Forecast 124
8.1.2 Key Events 127
8.1.3 Drivers and Barriers – Global Issues 127
8.1.4 Drivers and Barriers 129
9 Appendix 132
9.1 Bibliography 132
9.2 Abbreviations 137
9.3 Methodology 141
9.4 Forecasting Methodology 141
9.4.1 Diagnosed MDD Patients 141
9.4.2 Percent of Drug-Treated Patients 141
9.4.3 Drugs Included in Each Therapeutic Class 142
9.4.4 Launch and Patent Expiry Dates 142
9.4.5 General Pricing Assumptions 143
9.4.6 Individual Drug Assumptions 144
9.4.7 Generic Erosion 147
9.4.8 Pricing of Pipeline Agents 148
9.5 Physicians and Specialists Included in this Study 149
9.6 About the Authors 151
9.6.1 Analyst 151
9.6.2 Therapy Area Directors 151
9.6.3 Global Head of Healthcare 152
9.7 About GlobalData 153
9.8 Disclaimer 153

1.1 List of Tables
Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 18
Table 2: Subtypes of Major Depressive Disorder 19
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 21
Table 4: Treatment Guidelines for Major Depressive Disorder 22
Table 5: Most Prescribed Drugs for MDD by Class in Australia, 2013 22
Table 6: Country Profile - Australia 28
Table 7: Leading Treatments for MDD, 2013 30
Table 8: Product Profile - Lexapro 32
Table 9: Safety of Lexapro - Five Most Frequently Reported Adverse Events 34
Table 10: Lexapro SWOT Analysis, 2014 34
Table 11: Relative Frequency of Common Adverse Effects for Different SSRIs 38
Table 12: Product Profile - Effexor 40
Table 13: Effexor SWOT Analysis, 2014 42
Table 14: Product Profile - Cymbalta 44
Table 15: Cymbalta SWOT Analysis, 2023 46
Table 16: Product Profile - Pristiq 47
Table 17: Efficacy of Pristiq in short-term studies 48
Table 18: Pristiq SWOT Analysis, 2014 50
Table 19: Product Profile - Bupropion 52
Table 20: Safety of Bupropion - Five Most Frequently Reported Adverse Events 53
Table 21: Bupropion SWOT Analysis, 2014 54
Table 22: Product Profile - Mirtazapine 56
Table 23: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events 57
Table 24: Mirtazapine SWOT Analysis, 2014 58
Table 25: MAOI SWOT Analysis, 2014 60
Table 26: TCAs SWOT Analysis, 2014 62
Table 27: Product Profile - Brintellix 64
Table 28: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials 65
Table 29: Safety of Brintellix - Five Most Frequently Reported Adverse Events 67
Table 30: Brintellix SWOT Analysis, 2014 67
Table 31: Product Profile - Abilify 69
Table 32: Safety of Abilify - Five Most Frequently Reported Adverse Events 71
Table 33: Abilify SWOT Analysis, 2014 71
Table 34: Product Profile - Seroquel XR 73
Table 35: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants 74
Table 36: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events 75
Table 37: Seroquel XR SWOT Analysis, 2014 75
Table 38: Summary of Minor Therapeutic Classes in MDD, 2013 76
Table 39: Unmet Needs and Opportunities in MDD 78
Table 40: Comparison of Therapeutic Classes in Development for MDD, 2013 87
Table 41: Product Profile - Brexpiprazole 90
Table 42: Safety of Brexpiprazole - Most Frequently Reported Adverse Events 92
Table 43: Brexpiprazole SWOT Analysis, 2014 94
Table 44: Product Profile - Cariprazine 96
Table 45: Cariprazine SWOT Analysis, 2014 99
Table 46: Product Profile - ALKS-5461 101
Table 47: ALKS-5461 SWOT Analysis, 2014 104
Table 48: Product Profile - Amitifadine 106
Table 49: Amitifadine SWOT Analysis, 2014 109
Table 50: Product Profile - GLYX-13 110
Table 51: GLYX-13 SWOT Analysis, 2014 113
Table 52: Product Profile - Tedatioxetine 115
Table 53: Tedatioxetine SWOT Analysis, 2014 117
Table 54: Product Profile - ETS6103 119
Table 55: ETS6103 SWOT Analysis, 2014 122
Table 56: Drugs in Development for MDD, 2014 123
Table 57: Sales Forecasts ($m) for MDD in Australia, 2013-2023 125
Table 58: Key Events Impacting Sales for MDD in Australia, 2013-2023 127
Table 59: MDD Market - Drivers and Barriers, 2013-2023 127
Table 60: MDD Market in Australia - Drivers and Barriers, 2013-2023 129
Table 61: Key Launch Dates 142
Table 62: Key Patent Expiries 143
Table 63: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 15

1.2 List of Figures
Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 17
Figure 2: Disease Management Model for Major Depressive Disorder 24
Figure 3: Major Depressive Disorder Treatment Algorithm 26
Figure 4: MDD - Phase IIb-III Pipeline, 2014 86
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023 87
Figure 6: Clinical and Commercial Positioning of Brexpiprazole 93
Figure 7: Clinical and Commercial Positioning of Cariprazine 98
Figure 8: Clinical and Commercial Positioning of ALKS-5461 103
Figure 9: Clinical and Commercial Positioning of Amitifadine 108
Figure 10: Clinical and Commercial Positioning of GLYX-13 112
Figure 11: Clinical and Commercial Positioning of Tedatioxetine 116
Figure 12: Clinical and Commercial Positioning of ETS6103 121
Figure 13: Sales for MDD in Australia by Drug Class, 2013-2023 126

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • デジタルコンテンツの世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2021)
    Digital content industry is an important component of the digital economy. The so-called digital content industry is the use of digital high-tech tools and information technology to integrate the image, text, images, audio and other content into products and services. Digital content is stored on ei …
  • 小児手首舎の世界市場
    Pediatric Wrist Outhouses Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United Stat …
  • 通信市場:ガーナ
    This report is a comprehensive research of telecommunication industry in Ghana. The first two chapters of the report feature the country profile by giving general information on Ghana and by thoroughly studying its economic state, (including key macroeconomic indicators and their development trends) …
  • 中国のコークス(石炭燃料)市場動向(2014-2018)
    Description Coke is widely used in the fields of blast furnace iron-making, cupola iron melting, ferroalloy smelting and non-ferrous metals smelting. As a reducing agent, energy source and carbon agent, coke is also used as a raw material in carbide production, gasification and synthetic chemistry. …
  • Diamedix Corporation(医療機器分野):企業M&A動向
    Summary Diamedix Corporation (Diamedix) is a medical device company. The company conducts research and develops immunodiagnostic products. It develops products and procedures for autoimmune and infectious disease detection. Its products include diagnostics, instrumentation and non clinical. Diamedix …
  • チリのホルムアルデヒド市場2015-2019
    About The report brings together facts and figures about formaldehyde market in Chile covering period of 2009-2019. Statistics, experts’ opinions and estimations are given. The report about formaldehyde market in Chile covers: - manufacturers capacity, production volumes - company profiles - consump …
  • 口内炎治療薬の世界市場:ゲル、スプレー、マウスウォッシュ、錠剤
    About mouth ulcers Mouth ulcers are sores that form in the mucous membranes of the oral cavity. They are noncritical and do not pose a health hazard. Mouth ulcers can be caused by oral injury or may arise as a result of underlying disease. They can be associated with intense or moderate pain. The et …
  • パキスタンの医療用家具(歯科用診療チェア、その他)市場(~2020):市場規模、動向、予測
    The report Medical Furniture Market in Pakistan to 2020 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for medical furniture in Pakistan. The research includes historic data from 2009 to 2015 and forecasts until 2 …
  • アイルランドのブーツ市場(~2019)
    The report Boot Market in Ireland to 2019 - Market Size, Development, and Forecasts offers the most up-to-date industry data on the actual market situation, and future outlook for boots in Ireland. The research includes historic data from 2008 to 2014 and forecasts until 2019 which makes the report …
  • 中国の工業用ガス市場予測(生産、需要、市場規模)
    This study focuses on China’s Industrial Gases industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDHC245CFR )"オーストラリアにおける大うつ病性障害治療薬の市場予測及び分析(~2023)" (英文:PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023)はGlobalData社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。